23andMe Investor Presentation Deck
>90%
of 23andMe+
members receive a
report with
meaningful genetic
results
18,000+
Customers with an
increased risk for Chronic
Kidney Disease
8,000+ 12,000+
Customers with
a tested BRCA1 /
BRCA2 variant
Customers with
Hypercholesterolemia
(FH) variants
Note: Estimates based on prevalence of variants in 23andMe's Database as of September 30, 2022.
Providing Customers
With Key, Actionable
Insights
"Like me, there are many women who have slipped through the cracks of our
current medical screening system, either because they don't have a family
history of breast or ovarian cancer. Or they do not know that they have
Ashkenazi Jewish ancestry. In my case, even though I know I have Ashkenazi
ancestry, that wasn't enough to prompt my doctor to consider screening. So
there are many women walking around with this risk, who, like me, would have
never known of their own risk but for this test from 23andMe."
23andMe customer who discovered she had a BRCA1 mutationView entire presentation